Novacyt (FR:ALNOV) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Novacyt has achieved EU IVDR accreditation for its Yourgene® Cystic Fibrosis Base assay, marking it as one of the first CF tests to comply with the new rigorous standards. This accreditation assures the test’s quality and accuracy, enhancing its credibility among clinicians and patients across the EU and globally. With the potential for increased market momentum, especially in regions like Australia where reimbursement pathways have expanded, Novacyt’s position in the CF diagnostics market is set to strengthen.
For further insights into FR:ALNOV stock, check out TipRanks’ Stock Analysis page.
